CompanyCompetitive AnalysisCompany Patent Opposition Analysis

Explore Bristol Myers Squibb's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Jul 31, 2025
Patent NumberGrant DateTitleTotal Oppositions
Mar 20, 2024Apixaban Formulations1
Feb 28, 2024Methods Of Producing Recombinant Proteins5
Sep 13, 2023Treatment Of Lag-3 Positive Tumors2
Sep 6, 2023Methods For Increasing The Efficiency Of Homology Directed Repair (Hdr) In The Cellular Genome2
Aug 16, 2023Bispecific Antibodies Against Cd3Epsilon And Bcma For Use In Treatment Of Diseases3
Jun 28, 2023Pd-1 Blockade With Nivolumab In Refractory Hodgkin'S Lymphoma2
Jun 28, 2023Use Of An Anti-Pd-1 Antibody In Combination With An Anti-Cd30 Antibody In Lymphoma Treatment1
May 10, 2023Pharmaceutical Formulations Containing Dapagliflozin Propylene Glycol Hydrate5
Oct 27, 2021Use Of Anti-Pd-1 Antibody In The Treatment Of Patients With Colorectal Cancer6
Mar 10, 2021Treatment Of Pd-L1-Positive Melanoma Using An Anti-Pd-1 Antibody5